BWP
TGTX icon

Baldwin Wealth Partners’s TG Therapeutics TGTX Stock Holding History

Baldwin Wealth Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,000
Closed -$67K – 705
2022
Q1 		$67K Buy
7,000
+5,000
+250% +$57.9K 0.01% 329
2021
Q4 		$38K Hold
2,000
– – ﹤0.01% 383
2021
Q3 		$67K Hold
2,000
– – 0.01% 315
2021
Q2 		$78K Hold
2,000
– – 0.01% 302
2021
Q1 		$96K Hold
2,000
– – 0.01% 263
2020
Q4 		$104K Sell
2,000
-15,850
-89% -$536K 0.01% 240
2020
Q3 		$478K Hold
17,850
– – 0.07% 106
2020
Q2 		$348K Hold
17,850
– – 0.05% 119
2020
Q1 		$176K Sell
17,850
-10,000
-36% -$126K 0.03% 153
2019
Q4 		$309K Sell
27,850
-2,000
-7% -$15.2K 0.04% 146
2019
Q3 		$168K Hold
29,850
– – 0.03% 185
2019
Q2 		$258K Hold
29,850
– – 0.04% 183
2019
Q1 		$240K Buy
29,850
+12,000
+67% +$64.9K 0.04% 187
2018
Q4 		$73K Hold
17,850
– – 0.01% 252
2018
Q3 		$100K Hold
17,850
– – 0.01% 250
2018
Q2 		$235K Hold
17,850
– – 0.04% 182
2018
Q1 		$253K Hold
17,850
– – 0.04% 177
2017
Q4 		$146K Hold
17,850
– – 0.02% 215
2017
Q3 		$212K Hold
17,850
– – 0.03% 186
2017
Q2 		$179K Hold
17,850
– – 0.03% 195
2017
Q1 		$208K Hold
17,850
– – 0.03% 183
2016
Q4 		$83K Buy
17,850
+2,000
+13% +$11.7K 0.02% 249
2016
Q3 		$123K Hold
15,850
– – 0.02% 207
2016
Q2 		$96K Buy
15,850
+3,000
+23% +$24.4K 0.02% 211
2016
Q1 		$109K Sell
12,850
-2,000
-13% -$17.5K 0.02% 231
2015
Q4 		$177K Hold
14,850
– – 0.03% 215
2015
Q3 		$150K Buy
14,850
+900
+6% +$13.4K 0.03% 222
2015
Q2 		$231K Sell
13,950
-1,000
-7% -$15.8K 0.03% 215
2015
Q1 		$231K Buy
14,950
+1,000
+7% +$15.1K 0.03% 214
2014
Q4 		$221K Buy
13,950
+2,750
+25% +$35.8K 0.03% 224
2014
Q3 		$120K Buy
+11,200
New +$104K 0.02% 247

Other funds holding TGTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baldwin Wealth Partners's TGTX Position: Q2 2022 in Review

Baldwin Wealth Partners sold out of TG Therapeutics (TGTX) in Q2 2022, closing a stake of 7,000 shares — an estimated $67K sold.

Baldwin Wealth Partners first reported a position in TGTX in Q3 2014 and held it in 31 quarters. The position peaked at $478K in Q3 2020. 174 funds tracked by Wall St. Rank hold TGTX as of Q2 2022.

  • Baldwin Wealth Partners reported no remaining TG Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Baldwin Wealth Partners sold 7,000 TG Therapeutics shares in Q2 2022, an estimated $67K.
  • Baldwin Wealth Partners first reported a position in TG Therapeutics in Q3 2014 and held it in 31 quarters.
  • Baldwin Wealth Partners's TG Therapeutics position peaked at $478K in Q3 2020.
  • 174 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2022.

Based on Baldwin Wealth Partners's 13F filing for Q2 2022, filed 18 Jul 2022.